Cancer Prevention and Research Institute of Texas

The funding is part of a total of $16.6 million from CPRIT to support cancer research at and recruit scientists to the medical center.  

The registry is expected to yield a "validated, semi-quantitative risk assessment algorithm that will assist physicians in managing patients at risk for ovarian cancer."

NEW YORK (GenomeWeb News) – Several Texas biomedical science centers have received millions in new funding from the Cancer Prevention and Research Institute of Texas to support a wide range of studies, including 'omics-based projects, aimed at preventing, diagnosing, treating, and understanding c

The network will function as a "conduit" for academic researchers, community physicians, biotechnology companies, and drug manufacturers "to increase the pace of clinical oncology research by testing novel concepts, drugs, diagnostics, and medical devices," and provide state-of-the art care to patients in Texas, CTNET said.

The award will enable Rules-Based Medicine to add to its OncologyMAP panel immunoassays for 150 to 180 blood-based protein biomarkers associated with cancer.

The $3 million award will go toward developing and validating multiplexed immunoassays that measure 150 to 180 blood-based biomarkers that the National Cancer Institute believes may be associated with cancer.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.